Key result
A 46-year-old man with factor V Leiden mutation developed simultaneous subacute stent thrombosis in two different vessels four days after receiving sirolimus- and paclitaxel-eluting stents.
Why the study?
Does factor V Leiden mutation increase the risk of subacute stent thrombosis in patients receiving drug-eluting stents?
Population
46-year-old man who underwent elective percutaneous coronary intervention and stenting of the left anterior…
Design
Case_report
Follow-up
4 days
Authors
Loading...
May link factor V Leiden to subacute DES thrombosis; hypothesis-generating, should not yet change practice.
Case Report (n=1)
Does factor V Leiden mutation increase the risk of subacute stent thrombosis in patients receiving drug-eluting stents?
Factor V Leiden mutation may play a significant role in the development of acute and subacute coronary stent thrombosis following the placement of drug-eluting stents.
Eshtehardi et al. (2008) conducted a case report in Subacute coronary drug-eluting stent thrombosis (n=1). Factor V Leiden mutation was evaluated on Subacute stent thrombosis. A 46-year-old man with factor V Leiden mutation developed simultaneous subacute stent thrombosis in two different vessels four days after receiving sirolimus- and paclitaxel-eluting stents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: